Specialty Pharmacy

Stem cell transplantation found to provide greater protection than disease-modifying therapy against progression of relapsing-remitting multiple sclerosis.

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA discusses the emerging influence of NCODA chemotherapy education and standardization process for healthcare providers, healthcare systems, and patients.

The ever-growing price tag for new specialty drugs is testing the limits of the health care system to afford these revolutionary therapies.

With this approval, dupilumab (Dupixent) offers a biologic therapy option for patients 12 to 17 years of age who have moderate-to-severe atopic dermatitis.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, talks about new therapeutic developments going on within the prostate cancer space.

Top news of the day from across the health care industry.

M restricta was elevated in patients with Crohn disease carrying a genetic variation known as the IBD CARD9 risk allele.

Because pregnancy is one of the few times individuals are in contact with the health system and covered by health insurance, there is a cost-effective opportunity to screen for hepatitis C virus.

The FDA recently published an updated draft guidance on the naming of biologics, biosimilars, and interchangeable biosimilars.

Dupilumab (Dupixent, Regeneron and Sanofi) would be the first FDA-approved biologic for the treatment of severe chronic rhinosinusitis with nasal polyps.

Top news of the day from across the health care industry.

Top news of the week from Specialty Pharmacy Times.

If approved, rilpivirine plus cabotegravir would be the first monthly dosing option for adult patients with HIV.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more.

Patient-driven recommendations to reduce breast cancer-related economic burden could be key to shaping policies and interventions.

The supplemental new drug application for venetoclax in combination with obinutuzumab is being reviewed under the FDA’s Real-Time Oncology Review pilot program for patients with previously-untreated chronic lymphocytic leukemia.

Study focuses on the importance of distinguishing whether sugar-sweetened beverages heightened disability in patients with multiple sclerosis.

Top news of the day from across the health care industry.

The prevalence of multiple sclerosis in the United States has steadily grown over the past 5 years to nearly 1 million people.

Smaller entrepreneurial pharmacy owners are proactively pursuing the dispensing of specialty medications.

Officials with the FDA have approved esketamine CIII nasal spray (Spravato, Janssen Pharmaceutical Companies of Johnson & Johnson) for use in conjunction with an oral antidepressant in adults with treatment-resistant depression.

Ublituximab may provide a clinical benefit for patients with multiple sclerosis via lower doses and faster infusion times than current therapies.

Top news of the day from across the health care industry.

Approximately 1.7 million insured US patients are burdened with moderate to severe plaque psoriasis.

The CDC urges health care providers to implement its recommendations and to regularly review their facility infection data, among other intervention methods.

If approved, fedratinib would be the second FDA-approved treatment for myelofibrosis.

There are currently no approved therapies for the prevention of episodic cluster headaches.

Researchers have made progress in understanding why Hispanic children are disproportionately affected by acute lymphoblastic leukemia.